Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: A randomized clinical trial

British Journal of Haematology

Volumn 145, Issue 2, 2009, Pages 245-254

  Maggio, Aurelio ^a   Vitrano, Angela ^a   Capra, Marcello ^b   Cuccia, Liana ^b   Gagliardotto, Francesco ^b   Filosa, Aldo ^c   Romeo, Maria Antonietta ^d   Magnano, Carmelo ^e   Caruso, Vincenzo ^e   Argento, Crocetta ^f   Gerardi, Calogera ^g   Campisi, Saveria ^h   Violi, Pietro ⁱ   Malizia, Roberto ^j   Cianciulli, Paolo ^k   Rizzo, Michele ^l   D'Ascola, Domenico Giuseppe ^m   Quota, Alessandra ⁿ   Prossomariti, Luciano ^o   Fidone, Carmelo ^p   Rigano, Paolo ^a   Pepe, Alessia ^q   D'Amico, Gennaro ^r   Morabito, Alberto ^s   Gluud, Christian ^t   more..

^a UOC Ematologia II con Talassemia   (Italy)

^b Centro di Prevenzione Diagnosi e Cura della Talassemia   (Italy)

^c AO Cardarelli   (Italy)

^d Clinica Pediatrica i   (Italy)

^e ARNAS Garibaldi   (Italy)

^f AO S Giovanni di Dio   (Italy)

^g AOOCR ^*  (Italy)

^h UOS Centro Microcitemia   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j UOC Pediatria II   (Italy)

^k AO S Eugenio   (Italy)

^l UOC Ematologia   (Italy)

^m Centro Microcitemia   (Italy)

ⁿ UOC Medicina Trasfusionale   (Italy)

^o Centro Regionale per la Cura delle Microcitemie   (Italy)

^p U O C Centro Trasfusionale   (Italy)

^q FONDAZIONE TOSCANA GABRIELE MONASTERIO   (Italy)

^r UOC Gastroenterologia   (Italy)

^s UNIVERSITY OF MILAN   (Italy)

^t Rigshospitalet   (Denmark)

more..

Author keywords

Chelation; Clinical trials; Iron overload; Red blood cell disorders; Thalassaemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DRUG COST; DRUG DOSE REDUCTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SURVIVAL RATE; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, SUBCUTANEOUS; IRON CHELATING AGENTS; KAPLAN-MEIERS ESTIMATE; MALE; PYRIDONES; THALASSEMIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63149177947     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07609.x     Document Type: Article

References (38)

1. Abdelrazik, N. (2007) Pattern of iron chelation therapy in Egyptian beta thalassemic patients: Mansoura University Children's Hospital experience. Hematology, 12, 577 585.
2. Al-Refaie, F.N., Veys, P.A., Wilkes, S., Wonke, B. Hoffbrand, A.V. (1993) Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one. Acta Haematologica, 89, 86 90.
3. Al-Refaie, F.N., Wilkes, S., Wonke, B. Hoffbrand, A.V. (1994) The effect of deferiprone (L1) and desferrioxamine on myeolopiesis using a liquid culture system. British Journal of Haematology, 87, 196 198.
4. Aydinok, Y., Nisli, G., Kavakli, K., Coker, C., Kantar, M. Cetingül, N. (1999) Sequential use of deferiprone and desferioxamine in primary school children with thalassemia major in Turkey. Acta Haematologica, 102, 17 21.
5. Aydinok, Y., Ulger, Z., Nart, D., Terzi, A., Cetiner, N., Ellis, G., Zimmermann, A. Manz, C. (2007) A randomised controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica, 92, 1599 1606.
6. Borgna-Pignatti, C., Rugolotto, S., De Stefano, P., Zhao, H., Cappellini, M.D., Del Vecchio, G.C., Romeo, M.A., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A. Cnaan, A. (2004) Survival and complications in patients with thalassemia major treated with transfusion and desferrioxamine. Haematologica, 89, 1187 1193.
7. Borgna-Pignatti, C., Cappellini, M.D., De Stefano, P., Del Vecchio, G.C., Forni, G.L., Gamberini, M.R., Ghilardi, R., Piga, A., Romeo, M.A., Zhao, H. Cnaan, A. (2006) Cardiac morbidity in deferoxamine or deferiprone-treated patients with thalassaemia major. Blood, 107, 3733 3737.
8. Ceci, A., Baiardi, P., Felisi, M., Cappellini, M.D., Carnelli, V., De Sanctis, V., Galanello, R., Maggio, A., Masera, G., Piga, A., Schettini, F., Stefàno, I. Tricta, F. (2002) The safety and effectiveness of deferiprone in a large scale 3 years study in Italian patients. British Journal of Haematology, 118, 330 336.
9. Ceci, A., Baiardi, P., Catapano, M., Felisi, M., Cianciulli, P., De Sanctis, V., Del Vecchio, G.C., Magnano, C., Meo, A. Maggio, A. (2006) Risk factors for death in patients with β-thalassaemia major: results of a case-control study. Haematologica, 91, 1420 1421.
10. Cogliandro, T., Derchi, G., Mancuso, L., Mayer, M.C., Pannone, B., Pepe, A., Pili, M., Bina, P., Cianciulli, P., De Sanctis, V. Maggio, A., Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE) 2008) Guideline recommendations for heart complications in thalassemia major. The Journal of Cardiovascular Medicine, 9, 515 525.
11. Cohen, A.R., Galanello, R., Piga, A., Dipalma, A., Vullo, C. Tricta, F. (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology, 108, 305 312.
12. Delea, T.E., Edelsberg, J., Sofrygin, O., Thomas, S.K., Baladi, J.F., Phatak, P.D. Coates, T.D. (2007) Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 47, 1919 1929.
13. El-Beshlawy, A., Manz, C., Naja, M., Eltagui, M., Tarabishi, C., Youssry, I., Sobh, H., Hamdy, M., Sharaf, I., Mostafa, A., Shaker, O., Hoffbrand, A.V. Taher, A. (2008) Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Annals of Hematology, 87, 545 550.
14. Galanello, R., Kattamis, A., Piga, A., Fischer, R., Leoni, G., Ladis, V., Voi, V., Lund, U. Tricta, F. (2005) A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica, 91, 1241 1243.
15. Giardina, P.J. Grady, R.W. (2001) Chelation therapy in beta-thalassemia: an optimistic update. Seminars in Hematology, 38, 360 366.
16. Gomber, S., Saxena, R. Madan, N. (2004) Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatrics, 41, 21 27.
17. Ha, S.Y., Chik, K.W., Ling, S.C., Lee, A., Luk, C.W., Lam, C., Ng, I. Chan, G. (2006) A randomised controlled study on safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin, 30, 263 274.
18. Hedeker, D. Gibbons, R.D. (2006) Longitudinal Data Analysis. Hoboken Wiley, New Jersey.
19. Kattamis, A., Ladis, V., Berdousi, H., Kelekis, N.L., Alexopoulou, E., Papasotiriou, I., Drakaki, K., Kaloumenou, I., Galani, A. Kattamis, C. (2006) Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells, Molecules and Diseases, 36, 21 25.
20. Link, G., Konijn, A.M., Breuer, W., Cabantchik, Z.I. Hershko, C. (2001) Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. The Journal of Laboratory and Clinical Medicine, 138, 130 138.
21. Maggio, A., Giambona, A., Cai, S.P., Wall, J., Kan, Y.W. Chehab, F.F. (1993) Rapid and simultaneous typing of hemoglobin S, hemoglobin C and seven Mediterranean beta-thalassemia mutations by covalent reverse dot-blot analysis: application to prenatal diagnosis in Sicily. Blood, 81, 239 242.
22. Maggio, A., D'Amico, G., Morabito, A., Capra, M., Ciaccio, C., Cianciulli, P., Di Gregorio, F., Garozzo, G., Malizia, R., Magnano, C., Mangiagli, A., Quarta, G., Rizzo, M., D'Ascola, D.G., Rizzo, A. Midiri, M. (2002) Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells, Molecules and Diseases, 28, 196 208.
23. Maggio, A., D'Amico, G. Morabito, A. (2004) Independent clinical trials. The Lancet, 363, 108.
24. Maggio, A., Capra, M., Cuccia, L., Gagliardotto, F., Magnano, C., Caruso, V., Gerardi, C., Friscia, M.G., Argento, C., Campisi, S., Cantella, F., Cianciulli, P., Commendatore, F., D'Ascola, D.G., Fidone, C., Filosa, A., Fragasso, A., Galati, M., Giuffrida, G., Giugno, R., Lombardo, T., Malizia, R., Meo, A., Rizzo, M., Roccamo, G., Romeo, M.A., Violi, P., Pepe, A., D'Amico, G. Morabito, A. (2007) Deferiprone versus sequential deferiprone-deferoxamine treatment in thalassemia major: a five years multicenter randomised clinical trial under the auspices of the Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Blood, 110, 177a (Abstract # 575).
25. Modell, B. Berdoukas, V. (1984) The Clinical Approach to Thalassemia. Grune and Stratton, New York.
26. Olivieri, N.F. Brittenham, G.M. (1997) Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO). Blood, 90, 264a.
27. Olivieri, N.F., Koren, G., Hermann, C., Bentur, Y., Chung, D., Klein, J., St Louis, P., Freedman, M.H., McClelland, R.A. Templeton, D.M. (1990) Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. The Lancet, 336, 1275 1279.
28. Olivieri, N.F., Brittenham, G.M., Matsui, D., Berkovitch, M., Blendis, L.M., Cameron, R.G., McClelland, R.A., Liu, P.P., Templeton, D.M. Koren, G. (1995) Iron-chelation therapy with oral deferipronein patients with thalassemia major. The New England Journal of Medicine, 332, 918 922.
29. Origa, R., Bina, P., Agus, A., Crobu, G., Defraia, E., Dessì, C., Leoni, G., Muroni, P.P. Galanello, R. (2005) Combined therapy with desferrioxamine and deferiprone in thalassaemia major. Haematologica, 90, 1309 1314.
30. Pennell, D.J., Berdoukas, V., Karagiorga, M., Ladis, V., Piga, A., Aessopos, A., Gotsis, E.D., Tanner, M.A., Smith, G.C., Westwood, M.A., Wonke, B. Galanello, R. (2006) Randomised controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood, 107, 3738 3744.
31. Pepe, A., Positano, V., Santarelli, M.F., Sorrentino, F., Cracolici, E., De Marchi, D., Maggio, A., Midiri, M., Landini, L. Lombardi, M. (2006) Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Journal of Magnetic Resonance Imaging, 23, 662 668.
32. Piga, A., Gaglioti, G., Fogliacco, E. Tricta, F. (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassaemia major: a retrospective analysis. Haematologica, 88, 489 496.
33. Roberts, D.J., Brunskill, S.J., Doree, C., Williams, S., Howard, J. Hyde, C.J. (2007) Oral deferiprone for iron chelation in people with thalassemia. The Cochrane Library, 3, 1 56.
34. Rochon, J. (1991) Sample size calculations for two-group repeated-measures experiments. Biometrics, 47, 1383 1398.
35. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Roughton, M., Assomull, R., Nair, S.V., Walker, J.M. Pennell, D.J. (2007) A randomised, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation, 115, 1876 1884.
36. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A., Pibiri, M., Nair, S.V., Walker, J.M. Pennell, D.J. (2008) Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Journal of Cardiovascular Magnetic Resonance, 10, 12.
37. Telfer, P., Coen, P.G., Christou, S., Hadjigavriel, M., Kolnakou, A., Pangalou, E., Pavlides, N., Psiloines, M., Simamonian, K., Skordos, G., Sitarou, M. Angastiniotis, M. (2006) Survival of medically treated thalasemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematologica, 91, 1187 1192.
38. Vlachaki, E., Ioannidou-Papagiannaki, E., Tziomalos, K., Haralambidou-Vranitsa, S., Perifanis, V., Klonizakis, I. Athanassiou-Metaxa, M. (2007) Peripheral blood haematopoietic progenitor cells in patients with beta thalassaemia major receiving desferrioxamine or deferiprone as chelation therapy. European Journal of Haematology, 78, 48 51.